Open Payments

Mercyone Waterloo Medical Center

Type
Teaching hospital
Where
Saginaw, MI
Medicare CCN
160067
Received
$909,918 in 88 records, 2022 ($11,438 general, $898,479 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment23$11,438
2022Research payment65$898,479

By company

CompanyRecordsAmountYears
Eli Lilly and Company5$805,1342022
MicroPort Orthopedics Inc3$54,6192022
Esperion Therapeutics, Inc.55$26,2262022
Celgene Corporation1$10,5002022
Olympus America Inc.2$3,9332022
Siemens Medical Solutions USA, Inc.2$3,6832022
Linvatec Corporation1$2,2252022
Helsinn Healthcare SA1$2,0002022
Foundation Medicine, Inc.1$7702022
Barco, Inc.1$5142022
Merge Healthcare Incorporated16$3122022

By nature of payment

NatureRecordsAmount
Research payment65$898,479
Debt forgiveness4$7,617
Long term medical supply or device loan2$2,739
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$770
Food and Beverage16$312

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Linvatec Corporation$2,225Long term medical supply or device loanIn-kind items and servicesAIRSEAL Device, GENERAL SURGERY2022
2022-12-31Siemens Medical Solutions USA, Inc.$161Debt forgivenessIn-kind items and services2022
2022-12-28Foundation Medicine, Inc.$770Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentFOUNDATIONONE CDX Device, ONCOLOGY2022
2022-12-02Barco, Inc.$514Long term medical supply or device loanIn-kind items and servicesMDRC-2222 BL Device2022
2022-10-25Merge Healthcare Incorporated$70Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-10-05MicroPort Orthopedics Inc$10,731Research paymentCash or cash equivalentMPO Medial Pivot Knee Device, Orthopedic ProductPMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert2022
2022-09-13Celgene Corporation$10,500Research paymentCash or cash equivalentConnect MM- The Multiple Myeloma Disease Registry2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-09-12Merge Healthcare Incorporated$12Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-08-28Eli Lilly and Company$1,199Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022
2022-08-19Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-19Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-11Eli Lilly and Company$5,628Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM2022
2022-08-05Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$82Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$50Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$50Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$50Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-08-05Esperion Therapeutics, Inc.$50Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-28Siemens Medical Solutions USA, Inc.$3,522Debt forgivenessCash or cash equivalent2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-21Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-12Merge Healthcare Incorporated$21Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-07-12Merge Healthcare Incorporated$21Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-07-08Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$1,261Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$338Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$338Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-07-08Esperion Therapeutics, Inc.$226Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-06-10Merge Healthcare Incorporated$16Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-10Merge Healthcare Incorporated$16Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-10Merge Healthcare Incorporated$16Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-06-06MicroPort Orthopedics Inc$13,773Research paymentCash or cash equivalentMPO Medial Pivot Knee Device, Orthopedic ProductPMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert2022
2022-05-04MicroPort Orthopedics Inc$30,114Research paymentCash or cash equivalentMPO Medial Pivot Knee Device, Orthopedic ProductPMCF Study for Evolution Biofoam Tibia and Evolution CS/CR Porous Femur with Cruciate Sacrificing Insert2022
2022-05-03Eli Lilly and Company$315,458Research paymentCash or cash equivalentA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2022
2022-05-03Helsinn Healthcare SA$2,000Research paymentCash or cash equivalentA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamore2022
2022-04-25Esperion Therapeutics, Inc.$1,800Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-25Esperion Therapeutics, Inc.$586Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-25Esperion Therapeutics, Inc.$105Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2022
2022-04-21Merge Healthcare Incorporated$19Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-21Merge Healthcare Incorporated$19Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-21Merge Healthcare Incorporated$19Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-04-21Merge Healthcare Incorporated$19Food and BeverageCash or cash equivalentSoftware Device, Medical Imaging2022
2022-03-31Olympus America Inc.$2,258Debt forgivenessIn-kind items and servicesDORNHOFFER INTERPOSITIONALPORP W TITANIUM CRADLE3 MM OVERALL LENGTH 2 MM FUNCT Device, Ear, Nose, Throat2022
2022-03-31Olympus America Inc.$1,675Debt forgivenessIn-kind items and servicesOlympus Device, Urology Gynecology2022
2022-02-08Eli Lilly and Company$3,456Research paymentIn-kind items and servicesA STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE2022
2022-01-04Eli Lilly and Company$479,393Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Saginaw CountySaginaw city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Saginaw, MI, county Saginaw County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Saginaw, MI
County
Saginaw County, MI
State
Michigan
Population B0100343,536188,66510,077,761
Population, 2020 census P144,202190,12410,077,331
Median age B0100235.541.240.2
Under 18 B0100125.6%21.3%21.2%
65 and over B0100114.9%20.4%18.6%
Households B1100117,78977,9584,076,369
Foreign born B050021.4%2.4%7.2%
Median household income B19013$38,579$60,622$72,875
Median family income B19113$47,904$77,136$93,357
Per capita income B19301$21,177$34,578$40,735
Poverty rate B1700134.0%18.2%13.2%
Unemployment rate B2302510.1%6.4%5.7%
Civilian labor force B2302518,72987,5985,018,449
Mean commute (minutes) B0801319.222.424.2
Bachelor's degree or higher B1500313.3%24.4%32.4%
Housing units B2500121,06386,2084,622,236
Owner-occupied B2500360.0%74.1%73.2%
Renters B2500340.0%25.9%26.8%
Median home value B25077$60,000$152,800$231,600
Median gross rent B25064$922$947$1,129
White, not Hispanic B0300234.7%67.8%72.4%
Black B0300244.3%18.1%13.1%
Hispanic or Latino B0300215.9%9.2%5.9%
Asian B030020.2%1.2%3.4%
American Indian and Alaska Native B030020.1%0.1%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Saginaw, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.